Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 12th[th] March 2020 8:15am – 9:20am
Venue	Pathology Meeting Room, Pathology Dept, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Mr A Ramirez, Deputy Chief Pharmacist Dr O Ogunbambi, Consultant Rheumatologist Mr P O'Brien, Deputy Chief Pharmacist Dr S Raise, GP ER CCG (via phone link) Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr K McCorry, Medicines Optimisation Pharmacist, NECS (via phone link) Dr F Umerah, Consultant Anaesthetist Prof M Lind, Vice Chair, Professor of Oncology (via phone link)
Apologies	Dr H Klonin, Consultant Paediatrician Dr A Samson, Infectious Diseases Consultant Mr R Kapur, Vascular Surgeon Ms J Morgan, Professional Secretary, Senior Principal Pharmacist – Formulary

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed

2020.03.01	**Apologies**	As above					03.20
2020.03.03	**Declarations of Interest**	None					03.20
2020.03.03	**Minutes of the previous meeting**	Accepted as a true record					03.20
2020.03.04	**Action Tracker**	**New Product Request** ML to write to interventional radiology to request evidence relating to use of eptifibatide. ML has discussed with JM and will write before next meeting.	ML to feedback next time		ML	12.19	
		MHRA DSU AS to discuss risk of Hepatitis B virus reactivation with Dr Lilley. AS not present will discuss next time	AS to feedback next time		AS	03.20	
		F&WH Diclofenac to Ibuprofen JM has discussed with F&WH pharmacist who will raise at obstetrics governance meeting on 13th March	Action complete		JM		03.20
		IV Doxycycline as a Sclerosing Agent Surgery pharmacists have offered assistance to Mr Matteucci to write new product request form	Action complete		JM		03.20
		New Product Request Acarizax AM has written to the applicant with the committees decision	Action complete		AM		03.20
		NICE Guidance JM has requested an application for Lusutrombopag from gastroenterology in line with NICE T 67	Action complete		JM		03.20
		MHRA DSU JM has reviewed obstetric guideline and checked for ondansetron recommendations	Action complete		JM		03.20
		Terms of Reference					

		JM has added dietetics section to Tof R and sent to OQC for approval **Creatinine Clearance** JM has added to SMPC agenda **RMOC** JM has circulated feedback on SCF guidance to committee **Correspondence Received** WH has added Cephalexin to the trust formulary **Correspondence Received** JM has informed endocrinology that they can use biosimilar teriparatide	Action complete Action complete Action complete Action complete Action complete		JM JM JM WH JM		03.20 03.20 03.20 03.20 03.20
2020.03.05	**New Product Requests**	Tildarkizumab – Plaque Psoriasis – Dr Zaman Certolizumab pegol – Plaque Psoriasis – Dr Zaman Requested for use in line with NICE TA 445, to treat pregnant patients. POB mentioned that there had been issues with dermatology adhering to local guidance regarding the use of MABs, and it was agreed that a meeting would be arranged between dermatology and pharmacy to discuss this Ibandronic Acid – formulary extension (hypercalcaemia of malignancy – Kate Swain Requested for use in approx. 10 patients a year with poor renal function instead of zoledronic acid Relvar (extension of use) – Respiratory Medicine Originally approved as a red drug for use with DOT therapy. The committee agreed that if patients were compliant with DOT therapy and demonstrated improvement on Relvar is sensible to add Relvar to the asthma guideline and change traffic light status to blue – guideline led. The committee asked that it be clear on the updated guideline the duration of DOT therapy and the frequency of reassessment.	Approved in line with with NICE TA 575 Approved clinically but commissioning/ Adherence meeting must take place Approved AR to discuss updating asthma guideline with respiratory nurse and WH to add to HERPC agenda	AM to inform applicants and WH to update formulary AR to arrange for meeting with dermatology AR to request update to guideline	AM/WH AR AR		

		Brolucizumab (Beovu) nAMD – Miss L Downey Product requires less frequent applications than current agents which will relieve pressure on ophthalmology clinic services. NICE has not yet been published. KMc will discuss with CCG at meetings first week in April	AM to review evidence POB to prepare summary for KMc to take to CCG		AM POB		
2020.03.06	**NICE Guidance**	NG152 Leg ulcer infection: antimicrobial prescribing NG153 Impetigo: antimicrobial prescribing – recommends fucidic acid which is non formulary due to historical resistance NG154 Neonatal parenteral nutrition – HUTH paediatric pharmacist is reviewing against trust procedures If any differences are found this can be discussed further by D&T TA622 Sotagliflozin with insulin for treating type 1 diabetes – not on formulary TA623 Patiromer for treating hyperkalaemia – Originally requested in Sept 18 D&T rejected but agreed to revisit if NICE were published. TA624 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis TA597 Dapagliflozin with insulin for treating type 1 diabetes NG80Asthma: diagnosis, monitoring and chronic asthma management CG192Antenatal and postnatal mental health: clinical management and service guidance CG185 Bipolar disorder: assessment and management CG137Epilepsies: diagnosis and management	All AB on formulary AR to discuss with LC Endocrinology to be asked if they wish to use Add to formulary, if indications are the same as original application On formulary On formulary All updates - noted		AR AR WH	4.20 4.20 4.20	03.20 03.20 03.20
2020.03.07	**MHRA Drug Safety Update**	**February 2020** Ingenol Mebutate Gel: Suspension of the Licence due to the risk	Noted	No further			03.20

		of skin malignancy JM has written to Dr Zaman and informed her of the licence suspension and asked if dermatology would like to propose a substitute preparation		action			
		Lemtrada (Alemtuzumab) Updated Restrictions and Strengthened Monitoring Requirements following review of serious cardiovascular and immune mediated events Dr Harley is aware	Noted	No further action			03.20
		Valproate Pregancy Prevention Programme: Updated Educational Materials HUTH have tried to obtain local figures to confirm compliance but only national figures are available	Noted	No further action			03.20
		Nexplanon Contraceptive Implants New insertion site to reduce rare risk of neurovascular injury and implant migration Gynaecology and CHCP sexual health services are both aware of this.	Noted	No further action			03.20
2020.03.08	**Review Use of Aprotinin**	Aprotinin was approved by D&T in March 2019 for licensed use only. In line with this the trust must complete the company led database every time it is used. The database is a 100% complete for the 4 most recent patients and the cardiothoracic team are working backwards to ensure data on the 6 previous patients is complete the database must be 100% complete to be MHRA compliant	Review in 3 months	WH to add to June agenda	WH	04.20	
2020.03.09	**Second Switching of Biosimilars**	Due to the beneficial effect on the local health economy and recent RMOC guidance, the trust are looking at second switching some biosimilars with a potential cost saving of £1.2million. This work is only focusing on Rituximab, Infliximab and Etanercept at the moment. Although there is limited published information, there is no evidence to suggest second switching will result in patient harm and Rotherham and Southampton trusts have already proceeded with second switching with no evidence of adverse outcomes. The committee agreed that second switching was acceptable if appropriate follow up and monitoring are in place by the specialist services providing the treatment.	D&T Approved in principle second switching DC to ask improvement team to support pharmacists with second switching		DC	04.20	

2020.03.10	**Remdesivir for COVID 19 under compassionate use scheme**	NHSI have been in contact and requested the trust make plans to obtain Remdesivir in the event of patients admitted with COVID 19 requiring treatment. Remdesivir is not a licensed product and the company can only make available clinical trial stock from Switzerland. The committee reviewed the evidence and felt that it was of poor quality with no reference to potential toxicity or effectiveness in real patients. NHSI have not made it clear the criteria for giving the treatment. It was agreed that should a patient present and the ID team felt that they may benefit from the use of remdesivir it would be available after discussion with the chair.	Available via approval from chair	AR to inform ID team of committees decision	AR	04.20	
2020.03.11	**Minutes from SMPC**	None this month					03.20
2020.03.12	**Minutes from HERPC**	None this month					03.20
2020.03.13	**Regional Medicines Optimisation Committees**	None this month					03.20
2020.03 14	**Correspondence received**	Sodium Oxybate The trust has received an email from a patients parent. Requesting Sodium Oxybate be made available to her daughter who currently has to obtain from London. Currently funding for paediatric patients comes from NHSE but adult funding is via CCG. AM was happy to give chairs approval for this individual patient	AR to look into which consultants at HUTH would prescribe AR to forward email to POB		AR AR	04.20 04.20	
2020.03.15	**Chairs approvals**	Mercaptamine capsules 600mg and Levocarnitine 3mg for Cystinosis – Dr M Edey	Noted				03.20
2020.03.16	**Issues to escalate to OQC**	Nothing this month					03.20
2020.03.17	**Any Other Business**	None this month					03.20

	Date and Time of Next Meeting	**Date:** Thursday 9th April 2020 **Time:** 8.15-9.30am **Venue:** Pathology Meeting Room, HRI					